SCHEDULE OF DOCUMENTS - FOI-2557

ATTACHMENT A

Document No.	Date	Number of pages	Description	Decision on access ¹	Exemptions
1	16 October 2020	1	ATAGI COVID-19 Working Group Executive meeting outcomes	RIE	Section 22 (part) Section 47F (part)
2	10 December 2020	2	ATAGI COVID-19 Working Group Sub-Group 3 meeting outcomes	RI	Section 22 (part)
3	16 October 2020	1	ATAGI COVID-19 Working Group Sub-Group 3 meeting outcomes	RIE	Section 22 (part) Section 47F (part)
4	16 October 2020	3	ATAGI-COVID-19 Working Group Sub-Group 3 meeting outcomes	RIE	Section 22 (part) Section 47F (part)
5	16 October 2020	3	ATAGI COVID-19 Working Group Executive meeting outcomes	RIE	Section 22 (part) Section 47F (part)
6	26 November 2020	2	ATAGI COVID-19 Working Group Sub Group 3 meeting outcomes	RIE	Section 22 (part) Section 47F (part)
7	15 October 2020	13 (4 in scope)	ATAGI 77 th Draft Meeting Minutes	RIE	Section 22 (part) Section 47C (part) Section 47F (part)
8	17 December 2020	13 (3 in scope)	ATAGI 77th Draft Meeting Minutes	RIE	Section 22 (part) Section 47F (part)

¹ Release with Irrelevant and Exempt Information Removed

ATAGI COVID Working Group Videoconference, Meeting No. 6 16 October 2020, 12–1pm

Members	NCIRS Technical Staff	Department of He	alth reps
Allen Cheng (Co-chair)	s 47F	s 22	
Chris Blyth (Co-chair)	s 47F	s 22	
Katie Flanagan	s 47F	s 22	
Nigel Crawford	s 47F	s 22	
Robyn Gibbs	s 47F s 22		93
Kristine Macartney			
Lisa Schofield		Secretariat	
Nick Henderson		s 47F	
Hope Peisley		18	8
Agenda item		Purpose	Sponsor

Implementation considerations for COVID-19 vaccine
 Discuss
 No fault compensation / indemnity

Meeting close

s 22

Sharepoint page

https://healthgov.sharepoint.com/sites/secretariatcommittee/ATAGIC19/SitePages/Home.asp

Endorse: a decision is to be made at this meeting

Discuss: FOI 255 ecision is to be made at a future meeting or out of session of 1

Information: no decision points at this stage

ATAGI COVID Working Group Subgroup 3, Meeting No. 7 10 December 2020, 11:30 – 12:30pm

In attendance:

Members	NCIRS Technical Staff	Department of Health reps
Nigel Crawford - Lead	s 47F	s 22
Chris Blyth	s 47F	s 22
Allen Cheng	s 47F	s 22
Cheryl Jones	s 47F	s 22
Tony Korman		s 22
John Kaldor		s 22
I-Hao Cheng		s 22
Alan Leeb		s 22
Paul Effler		
Diane Walsh		
Margie Danchin		Secretariat
Debra Petrys		s 47F
Katie Attwell		s 47F
Kristine Macartney		£ 0.

s 22

4. Scenario walk through (Australian context)

Members DISCUSSED how to respond to likely scenarios following vaccine roll out such as:

s 22

• Poor vaccine sentiment and reduced uptake

s 22

s 22

Meeting closed at 12:40pm



ATAGI COVID Working Group Subgroup 3, Meeting No. 3

16 October 2020, 1:30 – 2:30pm

Members	NCIRS Technical Staff	Department of He	alth reps
Nigel Crawford- Lead	s 47F	s 22	
Allen Cheng	s 47F	s 22	
Cheryl Jones	s 47F	s 22	
Tony Korman	s 47F		
Margie Danchin	s 47F		
John Kaldor	s 47F		
I-Hao Cheng	s 47F	Secretariat	
Alan Leeb		s 47F	
Deb Petrys			
Paul Effler			
Agenda item		Purpose	Sponso

s 22

7. No fault vaccine compensation scheme	Discuss	Nigel Crawford	
---	---------	----------------	--

Document 3

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Vaccine Safety, Evaluation, Monitoring and Confidence Sub Group

Videoconference 1:30 - 2:30pm 16 October 2020

Outcomes

In attendance:

Members

Nigel Crawford (lead)

Chris Blyth

Tony Korman

Margie Danchin

I-Hao Cheng

Diane Walsh

Cheryl Jones

Alan Leeb

John Kaldor

Kristine Macartney

Department of Health representatives S 22

Secretariat A7F

47F

s 22

FOI 2557 1 of 3 Document 4

7. No fault Compensation scheme

Members:

s 22

• NOTED rather than a no fault compensation scheme, the advanced market agreements for COVID19 vaccines include an indemnity clause for the manufacturer.

THAS BEEN PRINT OF HEALTH

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #6 by Videoconference 16 October 2020, 12-1pm

Outcomes

In attendance:

Executive Members

Chris Blyth (Co-Chair)

Allen Cheng (Co-Chair)

Nick Henderson

Kristine Macartney

Hope Peisley

Katie Flanagan

Nigel Crawford

Robyn Gibbs

NCIRS support staff

s 47F

s4/H

Department of Health representatives

s 22

S 22

Secretariat

47F

s 47F

s 47F

4. Implementation considerations for COVID-19 vaccine Members:

s 22

DISCUSSED No fault compensation and providing indemnity to the manufacturer

ATAGI COVID Working Group Subgroup 3, Meeting No. 5 26 November 2020, 11:30 – 12:30pm

In attendance:

Members	NCIRS Technical Staff	Department of Health reps
Nigel Crawford- Lead	s 47F	s 22
Cheryl Jones	s 47F	
Tony Korman	s 47F	
John Kaldor	s 47F	
I-Hao Cheng	s 47F	Secretariat
Alan Leeb	s 47F	s 47F
Deb Petrys		s 47F
Paul Effler		

s 22

5. Safety advice

- ATAGI COVID19 WG3 Vaccine Safety preliminary advice DRAFT v1.2
- AESI for COVID19 vaccines 12112020 v3
- SARS MERS Vaccine Enhanced Disease Summary V2

Members AGREED to continue to refine the documents and incorporate inputs including:

 Revision of no-fault compensation scheme wording to make the subgroup's recommendation clearer

FOI 2557 1 of 2 Document 6

ATAGI COVID Working Group Subgroup 3, Meeting No. 5 26 November 2020, 11:30 – 12:30pm

s 22

FOI 2557 2 of 2 Document 6

Australian Technical Advisory Group on Immunisation (ATAGI) 77th meeting, by videoconference, 15 October 2020

Draft minutes

s 22

Item 9	Report from Chair and members on ATAGI business		9
	S		9
	9.1	No-fault compensation	9
	S	•	
	၁၁		
s 22			

1 of 4

In attendance:

Members

Associate Professor Chris Blyth (Co-Chair)

Professor Allen Cheng (Co-Chair)

Ms Karen Bellamy

Associate Professor Nigel Crawford

Professor Katie Flanagan

Dr Katherine Gibney

Associate Professor Michelle Giles

Ms Madeline Hall

Professor Cheryl Jones

Adjunct Associate Professor Tony Korman

Associate Professor Bette Liu

Ms Debra Petrys

Dr Nicholas Silberstein

Professor Tom Snelling

Ms Diane Walsh

Associate Professor James Wood

Nonvoting members

Dr Louise Flood

Dr Robyn Gibbs

Professor Kristine Macartney

Ms Hope Peisley

National Centre for Immunisation Research and Surveillance representatives (observers)

- s 47F
- S 4/F

Department of Health representatives

- s 22
- S 22
- s 22

Secretariat

- 47
- s 47F
- s 47F
- s 47F
- s 47F

Scribe

s 47F

Item 9 Report from Chair and members on ATAGI business

s 22

9.1 No-fault compensation

Associate Professor Crawford presented an update on no-fault compensation, as per the agenda papers. ATAGI noted that the issue is under discussion at high levels of government, and will also be discussed by ATAGI's COVID-19 vaccine safety, evaluation, monitoring and confidence subgroup.

s 47C s 47C

It had also been reported in the media that Australia does not have a no-fault compensation scheme. \$ 47C

s 47C

s 47C

Public confidence in COVID-19 vaccines could be significantly influenced by the presence or absence of a no-fault compensation scheme, and this may also affect public confidence in the NIP more broadly. Members noted the importance of anticipating and planning for various scenarios involving adverse events and COVID-19 vaccines.

ATAGI considered that more detailed information was needed to facilitate a fully informed discussion.

Action

No action arising.

Abbreviations and acronyms

Term	Definition
ACV	Advisory Committee on Vaccines
AIR	Australian Immunisation Register
ATAGI	Australian Technical Advisory Group on Immunisation
CDNA	Communicable Diseases Network Australia
CMO	Chief Medical Officer
Dol	declaration of interest
GRADE	Grading of Recommendations Assessment, Development and Evaluation
the Handbook	Australian Immunisation Handbook
JIC	Jurisdictional Immunisation Coordinators
NCIRS	National Centre for Immunisation Research and Surveillance
NHMRC	National Health and Medical Research Council
NIP	National Immunisation Program
NNDSS	National Notifiable Diseases Surveillance System
PBAC	Pharmaceutical Benefits Advisory Committee
PI	Product Information
QIV	quadrivalent influenza vaccine
SAGE	World Health Organization Strategic Advisory Group of Experts on Immunization
TGA	Therapeutic Goods Administration
TIV	trivalent influenza vaccine
TORs	terms of reference
WHO	World Health Organization

Australian Technical Advisory Group on Immunisation (ATAGI) 78th meeting, by videoconference, 11 December 2020

Draft minutes

s 22

Item 11	11 Report from Chair and members on ATAGI business		
		No-fault compensation and vaccine indemnity	

1 of 5

- -

In attendance:

Members

Associate Professor Chris Blyth (Co-Chair)

Professor Allen Cheng (Co-Chair)

Ms Karen Bellamy

Associate Professor Nigel Crawford

Professor Katie Flanagan

Dr Katherine Gibney

Associate Professor Michelle Giles

Ms Madeline Hall

Professor Cheryl Jones

Adjunct Associate Professor Tony Korman

Associate Professor Bette Liu

Ms Debra Petrys

Dr Nicholas Silberstein

Professor Tom Snelling

Ms Diane Walsh

Associate Professor James Wood

Nonvoting members

Mr Darius Everett

Dr Louise Flood

Dr Robyn Gibbs

Dr Catherine Kelaher

Professor Kristine Macartney

National Centre for Immunisation Research and Surveillance representatives (observers)

s 47F

s 22

Department of Health representatives

Secretariat

Ms Julianne Brettargh Ms Kylie Cornish-Martin Ms Tracie Hibbard Dr Allison Wyndham

Scribe

Dr Julie Irish, Biotext Pty Ltd



Item 11 Report from Chair and members on ATAGI business

No-fault compensation and vaccine indemnity 11.1

Associate Professor Crawford provided an update on no-fault compensation, as per the agenda papers. Members noted that ATAGI's position on no-fault compensation is communicated in the documents from the COVID-19 Working Group and subgroups, but that the government would be unlikely to take the issue further at this stage. It was also noted that Australia's cost-sharing frameworks mean that states and territories have a role in deliberating on no-fault compensation, and that state treasurers had not shown an interest in no-fault compensation in the past. Members considered that the work from ATAGI on this issue to date can be used in future discussions.

Action

No action arising.

Abbreviations and acronyms

Term	Definition
ACV	Advisory Committee on Vaccines
AIR	Australian Immunisation Register
ATAGI	Australian Technical Advisory Group on Immunisation
CDNA	Communicable Diseases Network Australia
CMO	Chief Medical Officer
Dol	declaration of interest
GRADE	Grading of Recommendations Assessment, Development and Evaluation
the Handbook	Australian Immunisation Handbook
JIC	Jurisdictional Immunisation Coordinators
NCIRS	National Centre for Immunisation Research and Surveillance
NHMRC	National Health and Medical Research Council
NIP	National Immunisation Program
NNDSS	National Notifiable Diseases Surveillance System
PBAC	Pharmaceutical Benefits Advisory Committee
PI	Product Information
QIV	quadrivalent influenza vaccine
SAGE	World Health Organization Strategic Advisory Group of Experts on Immunization
SoNG	Series of National Guidelines for public health units
TGA	Therapeutic Goods Administration
TIV	trivalent influenza vaccine
TORs	terms of reference
WHO	World Health Organization